Protagenic Therapeutics Current Valuation vs. Number Of Shares Shorted

PTIX Stock  USD 0.50  0.02  3.85%   
Based on Protagenic Therapeutics' profitability indicators, Protagenic Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Protagenic Therapeutics' ability to earn profits and add value for shareholders. At this time, Protagenic Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Days Of Sales Outstanding is likely to rise to 94.58 in 2024, whereas Price To Sales Ratio is likely to drop 0.28 in 2024. At this time, Protagenic Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 318.4 K in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (119.2 K) in 2024.
For Protagenic Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Protagenic Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Protagenic Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Protagenic Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Protagenic Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.27)
Return On Assets
(0.90)
Return On Equity
(2.06)
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Protagenic Therapeutics Number Of Shares Shorted vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Protagenic Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagenic Therapeutics value to that of its competitors to determine the firm's financial worth.
Protagenic Therapeutics is rated below average in current valuation category among its peers. It is rated below average in number of shares shorted category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Protagenic Therapeutics' earnings, one of the primary drivers of an investment's value.

Protagenic Current Valuation vs. Competition

Protagenic Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 10.93 Billion. Protagenic Therapeutics has negative current valuation of (1.32 Million) having no influence on the industry.

Protagenic Number Of Shares Shorted vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Protagenic Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(1.32 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Protagenic Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
98.44 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Protagenic Number Of Shares Shorted Comparison

Protagenic Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Protagenic Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Protagenic Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Protagenic Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Protagenic Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Protagenic Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-113.5 K-119.2 K
Operating Income-4.5 M-4.8 M
Income Before Tax-5 M-5.3 M
Total Other Income Expense Net-473.5 K-497.2 K
Net Loss-5 M-5.3 M
Income Tax Expense 2.00  1.90 
Net Loss-3.9 M-3.7 M
Net Loss-4.1 M-3.9 M
Net Interest Income176.5 K185.3 K
Interest Income303.2 K318.4 K
Change To Netincome1.7 M899.4 K
Net Loss(1.15)(1.21)
Income Quality 0.74  0.95 
Net Income Per E B T 0.91  0.76 

Protagenic Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Protagenic Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Protagenic Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Protagenic Therapeutics' important profitability drivers and their relationship over time.

Use Protagenic Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Protagenic Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagenic Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Protagenic Therapeutics Pair Trading

Protagenic Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Protagenic Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Protagenic Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Protagenic Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Protagenic Therapeutics to buy it.
The correlation of Protagenic Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Protagenic Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Protagenic Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Protagenic Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Protagenic Therapeutics position

In addition to having Protagenic Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Insurance Thematic Idea Now

Insurance
Insurance Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.